X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with FDC LTD. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs FDC LTD. - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA FDC LTD. GLENMARK PHARMA/
FDC LTD.
 
P/E (TTM) x 13.8 18.7 73.6% View Chart
P/BV x 3.9 3.9 98.9% View Chart
Dividend Yield % 0.3 1.2 27.1%  

Financials

 GLENMARK PHARMA   FDC LTD.
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
FDC LTD.
Mar-14
GLENMARK PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs1,262144 879.4%   
Low Rs67279 850.0%   
Sales per share (Unadj.) Rs270.647.6 568.8%  
Earnings per share (Unadj.) Rs24.97.6 326.9%  
Cash flow per share (Unadj.) Rs34.49.0 382.0%  
Dividends per share (Unadj.) Rs2.002.25 88.9%  
Dividend yield (eoy) %0.22.0 10.2%  
Book value per share (Unadj.) Rs151.347.5 318.4%  
Shares outstanding (eoy) m282.16177.83 158.7%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.62.3 152.8%   
Avg P/E ratio x38.914.6 265.8%  
P/CF ratio (eoy) x28.112.3 227.5%  
Price / Book Value ratio x6.42.3 272.9%  
Dividend payout %8.029.6 27.2%   
Avg Mkt Cap Rs m272,77819,784 1,378.8%   
No. of employees `00010.0NA-   
Total wages/salary Rs m13,7821,221 1,129.2%   
Avg. sales/employee Rs Th7,614.9NM-  
Avg. wages/employee Rs Th1,374.8NM-  
Avg. net profit/employee Rs Th700.2NM-  
INCOME DATA
Net Sales Rs m76,3408,459 902.5%  
Other income Rs m356394 90.5%   
Total revenues Rs m76,6968,852 866.4%   
Gross profit Rs m14,1722,070 684.6%  
Depreciation Rs m2,691249 1,080.4%   
Interest Rs m1,78931 5,768.8%   
Profit before tax Rs m10,0482,184 460.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,028606 500.1%   
Profit after tax Rs m7,0191,353 518.7%  
Gross profit margin %18.624.5 75.9%  
Effective tax rate %30.127.7 108.7%   
Net profit margin %9.216.0 57.5%  
BALANCE SHEET DATA
Current assets Rs m59,0964,355 1,356.9%   
Current liabilities Rs m40,0181,792 2,233.2%   
Net working cap to sales %25.030.3 82.5%  
Current ratio x1.52.4 60.8%  
Inventory Days Days7544 168.6%  
Debtors Days Days11925 483.2%  
Net fixed assets Rs m39,0753,025 1,291.7%   
Share capital Rs m282179 158.0%   
"Free" reserves Rs m30,2818,243 367.4%   
Net worth Rs m42,7038,453 505.2%   
Long term debt Rs m24,87311 232,457.9%   
Total assets Rs m111,02610,557 1,051.7%  
Interest coverage x6.671.4 9.3%   
Debt to equity ratio x0.60 46,015.3%  
Sales to assets ratio x0.70.8 85.8%   
Return on assets %7.913.1 60.5%  
Return on equity %16.416.0 102.7%  
Return on capital %17.523.5 74.5%  
Exports to sales %43.313.3 325.2%   
Imports to sales %7.43.3 222.2%   
Exports (fob) Rs m33,0441,126 2,935.4%   
Imports (cif) Rs m5,672283 2,005.8%   
Fx inflow Rs m36,9451,146 3,223.5%   
Fx outflow Rs m61,066355 17,187.2%   
Net fx Rs m-24,122791 -3,050.3%   
CASH FLOW
From Operations Rs m3,4491,485 232.2%  
From Investments Rs m-8,802-620 1,420.8%  
From Financial Activity Rs m6,986-753 -928.4%  
Net Cashflow Rs m934113 827.8%  

Share Holding

Indian Promoters % 48.3 68.9 70.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 4.7 146.8%  
FIIs % 34.4 7.5 458.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 19.0 55.3%  
Shareholders   56,727 23,730 239.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends in Red on Diwali Day; Bank & Metal Stocks Fall(Closing)

The hour-long auspicious Muhurat trading session ended on a weak note today. While the BSE Sensex closed lower by about 194 points.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

25 Things PM Modi Did Not Tell You About the Indian Economy(Vivek Kaul's Diary)

Oct 9, 2017

There are way too many data points out there which clearly show that all is not well with the Indian economy.

Electric Vehicles Boom: Stocks to Watch Out For(Smart Contrarian)

Oct 9, 2017

Are you creating a watch list of stocks for participating in the coming electric vehicles boom?

Timeless Stocks on the Electric Car Assembly Line(The 5 Minute Wrapup)

Oct 10, 2017

Are they on their way to create Coca Cola-like wealth?

Mutual Funds Re-categorised... But What About Stocks?(Daily Profit Hunter)

Oct 11, 2017

The market regulator can solve systemic issues but you must tackle the behavioral biases on your own.

9 Common, Yet Vital Questions On Personal Finance Answered(Outside View)

Oct 13, 2017

The answers to these 9 questions act as thumb rules to streamline your personal finances.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 19, 2017 07:33 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - PFIZER COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS